ONTX Onconova Therapeutics Inc.

0.35
+0.06  (+20%)
Previous Close 0.29
Open 0.37
Price To Book -2.19
Market Cap 13,456,612
Shares 38,447,462
Volume 41,209,406
Short Ratio
Av. Daily Volume 6,740,315
Stock charts supplied by TradingView

NewsSee all news

  1. Inceptua Medicines Access and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US

    NEWTOWN, Pa. and LUXEMBOURG, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova"), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat

  2. Onconova Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering

    NEWTOWN, Pa., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova"), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus

  3. Onconova Therapeutics, Inc. Announces $11.0 Million Public Offering

    NEWTOWN, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova"), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus

  4. Onconova Therapeutics Announces Exclusive License Agreement with Knight Therapeutics for Rigosertib in Canada

    Knight receives exclusive license to commercialize rigosertib in CanadaOnconova eligible to receive up to CAD 33.95 million in clinical, regulatory, and sales-based milestones and tiered double-digit royalties NEWTOWN,

  5. Onconova Announces Five Presentations on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2019 Annual Meeting & Exposition

    Oral presentation will feature efficacy and safety data from Expanded Phase 2 Trial of oral rigosertib in combination with azacitidine Four poster presentations to feature: biomarker genomic studies from

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 Special Protocol Assessment (SPA) submission announced January 2, 2019. Phase 2 presentation at ASH December 9, 2019, 7am ET.
Oral Rigosertib and azacitidine
First-line HR-MDS (high risk myelodysplastic syndromes)
Phase 3 data due 1H 2020.
IV Rigosertib - INSPIRE
2nd-line HR-MDS (high risk myelodysplastic syndromes)

Latest News

  1. Inceptua Medicines Access and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US

    NEWTOWN, Pa. and LUXEMBOURG, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova"), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat

  2. Onconova Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering

    NEWTOWN, Pa., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova"), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus

  3. Onconova Therapeutics, Inc. Announces $11.0 Million Public Offering

    NEWTOWN, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova"), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus

  4. Onconova Therapeutics Announces Exclusive License Agreement with Knight Therapeutics for Rigosertib in Canada

    Knight receives exclusive license to commercialize rigosertib in CanadaOnconova eligible to receive up to CAD 33.95 million in clinical, regulatory, and sales-based milestones and tiered double-digit royalties NEWTOWN,

  5. Onconova Announces Five Presentations on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2019 Annual Meeting & Exposition

    Oral presentation will feature efficacy and safety data from Expanded Phase 2 Trial of oral rigosertib in combination with azacitidine Four poster presentations to feature: biomarker genomic studies from

  6. Onconova Affirms Planned Completion of Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes by 1H20 And Provides Research & Development Update

    NEWTOWN, Pa., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a focus on

  7. Onconova Therapeutics, Inc. Announces $3.4 Million Registered Direct Offering of Common Stock

    NEWTOWN, Pa., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on

  8. Onconova Therapeutics Announces Termination of Proposed Public Offering

    NEWTOWN, Pa., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on

  9. Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit

    NEWTOWN, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on